Gilberto Gerra

Gilberto Gerra

Auto-generated profile, based on publicly available information

Gilberto Gerra

Drug Prevention and Health Branch, Division for Operations, United Nations Office on Drugs and Crime, Vienna, Austria

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2020 in Basic and Clinical Neuroscience Journal
Verified
Journal Article
Open access
PDF file
AFAli Farhoudian
Ali Farhoudian
ABAlexander Baldacchino
Alexander Baldacchino
NCNicolas Clark
Nicolas Clark
GGGilberto Gerra
Gilberto Gerra
HEHamed Ekhtiari
Hamed Ekhtiari
EREmran Mohammad Razaghi
Emran Mohammad Razaghi
Coronavirus disease 2019 (COVID-19) is escalating all over the world and has higher morbidities and mortalities in certain vulnerable populations. People who use drugs (PWUD) are a marginalized and stigmatized group with weaker immunity responses, vulnerability to stress, poor health conditions, high-risk behaviors, and lower access to health care services. These ...

1 January 2014 in Progress in Neuro-Psychopharmacology and Biological Psychiatry
Verified
Journal Article
Closed access
GGG. Gerra
G. Gerra
LSL. Somaini
L. Somaini
MMMatteo Manfredini
Matteo Manfredini
MRM.A. Raggi
M.A. Raggi
MSM.A. Saracino
M.A. Saracino
CDClaudia Donnini
Claudia Donnini

1 January 2014 in Psychiatry Research
Verified
Journal Article
Closed access
GGGilberto Gerra
Gilberto Gerra
LSLorenzo Somaini
Lorenzo Somaini
CLClaudio Leonardi
Claudio Leonardi
ECElena Cortese
Elena Cortese
IMIcro Maremmani
Icro Maremmani
CDClaudia Donnini
Claudia Donnini

1 May 2011 in Recent Patents on CNS Drug Discovery
Verified
Journal Article
Closed access
PDF file
LSLorenzo Somaini
Lorenzo Somaini
CDClaudia Donnini
Claudia Donnini
MRMaria A. Raggi
Maria A. Raggi
MAMario Amore
Mario Amore
RCRoberto Ciccocioppo
Roberto Ciccocioppo
GGGilberto Gerra
Gilberto Gerra
Cocaine dependence is characterized by compulsive drug seeking and high vulnerability to relapse. Overall, cocaine remains one of the most used illicit drugs in the world. Given the difficulty of achieving sustained recovery, pharmacotherapy of cocaine addiction remains one of the most important clinical challenges. Recent advances in neurobiology, brain imaging and clinical trials suggest that certain medications show promise in the treatment of cocaine addiction. The pharmacotherapeutic approaches for cocaine dependence include medications able to target specific subtypes of dopamine receptors, affect different neurotransmitter systems (i.e. noradrenergic, serotonergic, cholinergic, glutamatergic, GABAergic and opioidergic pathways), and modulate neurological processes. The systematic reviews concerning the pharmacological treatment of cocaine dependence appear to indicate controversial findings and inconclusive results. The aim of future studies should be to identify the effective medications matching the specific needs of patients with specific characteristics, abandoning the strategies extended to the entire population of cocaine dependent patients. In the present review we summarize the current pharmacotherapeutic approaches to the treatment of cocaine dependence with a focus on the new patents.

12 October 2009 in American Journal of Medical Genetics Part B: Neuropsychiatric Genetics
Verified
Journal Article
Closed access
PDF file
GGG. Gerra
G. Gerra
AZA. Zaimovic
A. Zaimovic
LCL. Castaldini
L. Castaldini
LGL. Garofano
L. Garofano
MMMatteo Manfredini
Matteo Manfredini
CDClaudia Donnini
Claudia Donnini

1 October 1994 in Acta Psychiatrica Scandinavica
Verified
Journal Article
Closed access
PDF file
GGG. Gerra
G. Gerra
RCR. Caccavari
R. Caccavari
AMA. Marcato
A. Marcato
AZA. Zaimovic
A. Zaimovic
PAP. Avanzini
P. Avanzini
FBF. Brambilla
F. Brambilla